Arcturus Therapeutics is trading at $9.57, down 11.96%, amid a broad market retreat, with no verified company-specific announcement explaining the November 5 decline. - Reuters reported the Nasdaq fell 3.2% as investors worried about AI spending and data-center scrutiny. - Provided sector context also showed biotechnology shares under pressure. - Third-quarter results and a corporate update were scheduled for after the market close, so they were not yet available at 11:00 a.m. ET.